Catheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University Hospital

Rhea-AI Summary

Catheter Precision (VTAK) has secured its first VIVO product purchase order from Sahlgrenska University Hospital (SUH) in Sweden. SUH, the largest hospital in Sweden, treats 350,000 patients annually and operates the region's largest ventricular ablation program. CEO David Jenkins emphasized the strategic importance of partnering with SUH as a teaching hospital, noting that training new physicians on their products creates future sales opportunities when doctors transition to other institutions. This development marks Catheter Precision's expansion into the Swedish market with their cardiac electrophysiology technology.

Positive

• First VIVO product order secured in Swedish market, marking international expansion
• Partnership with Sweden's largest hospital serving 350,000 patients annually
• Access to region's largest ventricular ablation program
• Strategic partnership with teaching hospital creates pipeline for future sales through trained physicians

Negative

• None.

SUH is the Largest Hospital in Sweden and a Highly Influential Center for VT in Scandinavia

FORT MILL, S.C., June 09, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced receipt of the first purchase order for their VIVO product from Sweden.

This newest purchase order comes from Sahlgrenska University Hospital, the largest hospital in Sweden with 350,000 patients per year. It is also the largest ventricular ablation program in the region.

“We are very excited to partner with Sahlgrenska University Hospital”, said David Jenkins, CEO of Catheter Precision, Inc. “Not only does this hospital perform many ventricular ablation procedures per year, but they are also a committed teaching hospital. Creating strong partnerships with teaching hospitals enables new physicians to be trained with our products and creating a new opportunity for future sales when that physician leaves the teaching institution.”

About VIVO
Catheter Precision’s VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

At the Company
David Jenkins
973-691-2000
info@catheterprecision.com

# # #

FAQ

What is the significance of VTAK's purchase order from Sahlgrenska University Hospital?

The purchase order represents Catheter Precision's first VIVO product sale in Sweden, partnering with the country's largest hospital that serves 350,000 patients annually and runs the region's largest ventricular ablation program.

How will the Sahlgrenska University Hospital partnership benefit VTAK's future sales?

As a teaching hospital, physicians trained on VTAK's products at Sahlgrenska may continue using them when they move to other institutions, creating future sales opportunities.

What is Catheter Precision's (VTAK) main business focus?

Catheter Precision is a US-based medical device company that develops advanced products for the cardiac electrophysiology market.

What is the size and reach of Sahlgrenska University Hospital?

Sahlgrenska University Hospital is the largest hospital in Sweden, treating 350,000 patients annually and operating the region's largest ventricular ablation program.